L'intérêt à découvert pour Lantheus Holdings donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Lantheus Holdings. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Lantheus Holdings (NASDAQ:LNTH) Stock, Rapport sur les intérêts à découvert

Lantheus Holdings

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings Inc

WIIM

LNTH

Lantheus Holdings shares are trading higher after the company announced its board authorized a $250 million share repurchase program.

News

Buybacks

Lantheus Board Authorizes $250M Share Repurchase Program

Lantheus Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NYSE">LNTH</a>) short percent of float has risen 3.19% since its last report. The company recently reported that it has 4.25 million shares sold short, which is 8.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lantheus Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731351612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lantheus Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lantheus Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lantheus Holdings's peer group average for short interest as a percentage of float is 7.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Lantheus Holdings?

<h3 class="wp-block-heading">Trump Will Fix It&nbsp;</h3>
In my previous post (<a href="https://www.zerohedge.com/news/2024-11-06/post-trump-victory-trade">The Post-Trump Victory Trade</a>), I highlighted a half dozen stocks in which my subscribers and I had positions that had double digit gains the day after Trump&#8217;s election victory. In response, a commenter wrote, &#8220;Well, I didn&#8217;t like any of those trades, so I will stick to my Gold and Silver.&#8221;.&nbsp;
As it happened, the day after Trump&#8217;s victory, was also the day of the &#8220;<a href="https://www.zerohedge.com/the-market-ear/great-gold-puke">Great Gold Puke</a>&#8220;, as The Market Ear put it:&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><h3 class="wp-block-heading">All good things&#8230;</h3>
&#8230;.must come to an end. Gold is puking, putting in the biggest down candle in forever as it breaks below the short term trend channel. The 50 day comes in around $2635, and the bigger trend line around $2600.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="532" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-1024x532.png" alt="" class="wp-image-3141" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-1024x532.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-300x156.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-768x399.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> 
<cite>Refinitiv</cite></blockquote>
Why would gold tumble after Trump&#8217;s victory? Perhaps there&#8217;s a clue in the Trump campaign&#8217;s slogan, &#8220;Trump will fix it&#8221;. One of the things Trump will fix is the elevated geopolitical risk the world has seen over the last few years, starting with the Russia-Ukraine War, and extending to the wars in the Mideast between Israel and Hamas, and Israel and Iran, and tensions between China and Taiwan.&nbsp;
<h3 class="wp-block-heading">Geopolitical Risk Is Already Starting To Ebb</h3>
The geopolitical risk premium is a key factor influencing the price of precious metals like gold and silver, as they are traditionally seen as a haven during times of instability and war. Given that, note what has happened since Trump&#8217;s victory:&nbsp;
<ul>
<li>Hamas <a href="https://x.com/DonaldJTrumpJr/status/1854516506169585796">has called for</a> an end to its war with Israel. </li>
<li>Russian President Vladimir Putin&nbsp;<a href="https://www.zerohedge.com/geopolitical/putin-praises-courageous-trump-hints-ukraine-talks-phone-call-likely">has congratulated Trump</a>&nbsp;on his victory, praised Trump&#8217;s bravery during the first assassination attempt on him, and expressed an openness toward talks aimed at ending the Ukraine war. Peace between the U.S. and Russia would facilitate peace in the Mideast and elsewhere, given Russia&#8217;s ties to Iran, China, and other key countries.&nbsp;</li>
<li>China&#8217;s President Xi <a href="https://x.com/XHNews/status/1854396381982830623">also extended congratulations</a> and an olive branch to Trump.</li>
</ul>
If Trump succeeds in ending the wars in Eastern Europe and the Mideast, and calming tensions across the Taiwan Strait, that would further reduce gold&#8217;s geopolitical risk premium.&nbsp;
<h3 class="wp-block-heading">The Deflationary Potential Of Trump&#8217;s Domestic Policies </h3>
You&#8217;re probably thinking now that even if peace starts to break out, high inflation is baked into the cake because of government spending, and that should boost the price of gold. Consider, though, the deflationary potential of Trump&#8217;s proposed policies, and those of his close allies.&nbsp;&nbsp;
<ul>
<li>Trump&#8217;s tariffs. Critics of tariffs often point out that they are, effectively, a regressive tax on domestic consumers. This is actually true, and like all regressive taxes, they are deflationary. Just as throwing money and low income Americans boosted inflation during COVID, an effective regressive tax on them would cool inflation.&nbsp;</li>
<li>Trump&#8217;s deportations.&nbsp;Deporting millions of illegal aliens&#8211;or deporting a smaller number and prompting millions more to self-deport&#8211;will have a deflationary effect on sectors such as housing, as there will be fewer consumers competing for the same number of homes.&nbsp;</li>
<li>RFK, Jr.&#8217;s campaign against chronic disease. Every case of diabetes and other chronic diseases RFK, Jr. can prevent with changes to American food policy means a reduction of tens of thousands, if not hundreds of thousands of dollars in health care spending. That would cool healthcare inflation.&nbsp;</li>
<li>Elon Musk&#8217;s Department Of Government Efficiency. Elon Musk has spoken about slashing the number of federal employees (something Vivek Ramaswamy pointed out could be done while avoiding Civil Service regulations) and cutting government waste. That would be deflationary too.&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Much Of This Is Likely To Happen&nbsp;</h3>
We all remember how Trump was stymied in his first term, but he is in a much stronger position now. He won a landslide victory, and is now the undisputed leader of the Republican Party. Plus, he has much smarter, and more competent people on his side now, such as Elon Musk. None of this is particularly good for gold and silver prices.&nbsp;
<h3 class="wp-block-heading">Taking My Own Counsel&nbsp;</h3>
On Thursday, I exited the two gold positions I had, in&nbsp;Olra Mining&nbsp;(ORLA) and IAMGOLD&nbsp;(IAG), as you can see below, in my list of trade exits for this week.&nbsp;
Stocks or Exchange Traded Products
<ol>
<li>Lantheus Holdings&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>). Bought at $94.84 on&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-8152024/comment/65674302" target="_blank" rel="noreferrer noopener">8/16/2024</a>; stopped out at $96.99 on&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-8152024/comment/75900731" target="_blank" rel="noreferrer noopener">11/6/2024</a>.&nbsp;Profit: 2.3%.</li>
<li>Orla Mining&nbsp;(<a href="https://substack.com/discover/stocks/ORLA" target="_blank" rel="noreferrer noopener">ORLA 4.11%↑</a>). Bought for an effective price of $2.90 on&nbsp;<a href="https://portfolioarmor.substack.com/p/an-oversold-gold-miner" target="_blank" rel="noreferrer noopener">11/17/2023</a>&nbsp;(I sold $5 strike puts on it for $2.10, and those puts exercised on 11/17/2023); sold for $4.60 on&nbsp;<a href="https://portfolioarmor.substack.com/p/an-oversold-gold-miner/comment/76086457" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 59%.</li>
</ol>
Options
<ol>
<li>Call spread on&nbsp;Super Micro Computer&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>). Entered at a net debit of $0.33 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-ai-da2" target="_blank" rel="noreferrer noopener">11/4/2024</a>; will expire worthless on 11/8/2024.&nbsp;Loss: 100%.</li>
<li>Calls on&nbsp;IAMGOLD&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>). Bought for $0.75 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-gold" target="_blank" rel="noreferrer noopener">10/8/2024</a>; sold (second half) for $1.15 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-gold/comment/76091886" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 53%.</li>
<li>Calls on&nbsp;Emergent BioSolutions&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>). Bought for $2.05 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-biotech" target="_blank" rel="noreferrer noopener">8/30/2024</a>; sold for $4.10 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-biotech/comment/76086955" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 100%.</li>
<li>Call spread on TG Therapeutics (<a href="https://substack.com/discover/stocks/TGTX" target="_blank" rel="noreferrer noopener">TGTX 2.33%↑</a>). Entered at net debit of $0.33 on <a href="https://portfolioarmor.substack.com/p/trade-alert-biotech" target="_blank" rel="noreferrer noopener">8/30/2024</a>; exited at a net credit of $0.94 on <a href="https://portfolioarmor.substack.com/p/trade-alert-biotech/comment/76253379" target="_blank" rel="noreferrer noopener">11/8/2024</a>. Profit: 184%.</li>
<li>Call spread on&nbsp;Tesla&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). Entered at a net debit of $1.63 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-evs/comment/76235063" target="_blank" rel="noreferrer noopener">4/8/2024</a>; exited at net credit of $4.74 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-evs/comment/76235063" target="_blank" rel="noreferrer noopener">11/8/2024</a>.&nbsp;Profit: 191%.</li>
<li>Call spread on&nbsp;Innodata&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>). Entered at $0.33 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-24f" target="_blank" rel="noreferrer noopener">8/13/2024</a>; exited at $0.97 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-24f/comment/76235562" target="_blank" rel="noreferrer noopener">11/8/2024</a>.&nbsp;Profit: 194%.</li>
<li>Call spread on&nbsp;Powell Industries&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>). Entered at a net debit of $1.60 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-industrial" target="_blank" rel="noreferrer noopener">8/13/2024</a>; exited at a net credit of $4.75 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-industrial/comment/76088210" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 197%.</li>
<li>Calls on&nbsp;Travelzoo&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>). Bought at $1 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-crypto" target="_blank" rel="noreferrer noopener">7/23/2024</a>; sold (half) at $8.30 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-crypto/comment/75897738" target="_blank" rel="noreferrer noopener">11/6/2024</a>.&nbsp;Profit: 730%.</li>
</ol>
<h2 class="wp-block-heading">The Post-Trump Victory Trade We&#8217;re Buying Now</h2>
Trump&#8217;s victory means China is going to have to stimulate its economy more aggressively (because it won&#8217;t be able to export as much to the U.S. with Trump&#8217;s tariff).&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;Donald Trump's second US presidency is likely to prompt aggressive China stimulus&quot; &#8211; Devan Kaloo, global head of equities at abrdn <a href="https://t.co/hVPBus1Bde">https://t.co/hVPBus1Bde</a>
&mdash; zerohedge (@zerohedge) <a href="https://twitter.com/zerohedge/status/1854379142952726692?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
That stimulus will boost companies doing business in China&#8217;s domestic market. One of those companies hit our&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-1172024">top ten names</a>&nbsp;last night, and my subscribers and I placed a trade on it today.&nbsp;
<figure class="wp-block-image size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-trump-china"><img loading="lazy" decoding="async" width="922" height="816" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade.jpg" alt="" class="wp-image-3142" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade.jpg 922w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade-300x266.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade-768x680.jpg 768w" sizes="(max-width: 922px) 100vw, 922px" /></a><figcaption class="wp-element-caption">Click on the image to go to the post. </figcaption></figure>
If you&#8217;d like a heads up when we place our next trade, feel free to subscribe to our trading Substack/occasional email list below.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1.jpg" alt="" class="wp-image-3152" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>
And if you are concerned about market risk, you can download our optimal hedging app by pointing your iPhone camera at the QR code below, or by clicking on it. 
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204833/QR-Code-2.jpg" alt="" class="wp-image-3155" /></a></figure>

Commodities

Economics

General

INOD

POWL

SMCI

TSLA

TZOO

After Trump's Win, It's Time To Take Profits On Gold

Truist Securities analyst Richard Newitter reiterates Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and lowers the price target from $135 to $120.

Price Target

Reiteration

Analyst Ratings

Truist Securities Reiterates Buy on Lantheus Holdings, Lowers Price Target to $120

JMP Securities analyst David Turkaly maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Market Outperform and lowers the price target from $125 to $112.

JMP Securities Maintains Market Outperform on Lantheus Holdings, Lowers Price Target to $112

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 77.9% to $7.49 during Wednesday's regular session. The company's market cap stands at $38.9 million. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares moved upwards by 29.22% to $7.03. The company's market cap stands at $924.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) stock increased by 23.78% to $7.13. The market value of their outstanding shares is at $443.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 21.63% to $2.98. The company's market cap stands at $104.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock moved upwards by 21.26% to $0.34. The market value of their outstanding shares is at $10.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 16.24% to $5.94. The company's market cap stands at $108.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) stock declined by 39.6% to $3.13 during Wednesday's regular session. The company's market cap stands at $335.3 million. As per the press release, Q3 earnings came out today. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 39.39% to $17.91. The market value of their outstanding shares is at $2.7 billion. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock declined by 31.98% to $0.09. The market value of their outstanding shares is at $1.5 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 31.5% to $1.74. The market value of their outstanding shares is at $1.8 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 27.36% to $51.95. The company's market cap stands at $9.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock decreased by 22.71% to $88.86. The market value of their outstanding shares is at $6.1 billion. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BJDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTKB

EXAS

OPRX

PACS

RAPT

SONN

TMCI

TNGX

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

Lantheus Holdings shares are trading lower. The company reported Q3 financial results and narrowed its FY24 guidance.

Full Year 2024 Financial Guidance&nbsp; Guidance Issued November 6, 2024 Guidance Issued July 31, 2024 FY 2024 Revenue $1.51 billion - $1.52 billion $1.50 billion - $1.52 billion FY 2024 Adjusted Fully Diluted EPS $6.65 - $6.70 $6.60 - $6.70

Earnings

Guidance

Lantheus Narrows 2024 Guidance: Now Sees Revenue Of $1.51B-$1.52B (Prior $1.50B-$1.52B) Vs. $1.52B Est., And Adj. EPS Of $6.65-$6.70 (Prior $6.60-$6.70) Vs. $6.66 Est.

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.56 by 8.97 percent. This is a 15.65 percent increase over earnings of $1.47 per share from the same period last year. The company reported quarterly sales of $378.734 million which beat the analyst consensus estimate of $371.681 million by 1.90 percent. This is a 18.37 percent increase over sales of $319.946 million the same period last year.

Earnings Beats

Lantheus Holdings Q3 2024 Adj. EPS $1.70 Beats $1.56 Estimate, Sales $378.734M Beat $371.681M Estimate

Lantheus Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NYSE">LNTH</a>) short percent of float has risen 3.19% since its last report. The company recently reported that it has 4.25 million shares sold short, which is 8.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lantheus Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730748618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lantheus Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lantheus Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lantheus Holdings's peer group average for short interest as a percentage of float is 7.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Lantheus Holdings's Recent Short Interest

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>).
On Oct. 29, Citigroup analyst Jon Tower maintained Cava Group with a Neutral and raised the price target <a href="https://www.benzinga.com/quote/CAVA/analyst-ratings">from $115 to $140.</a>
When asked about GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), he said, &#8220;You have to have planes last longer. And that means more GE business.&#8221;
On Oct. 22, GE Aerospace reported third-quarter 2024 adjusted revenue growth of 6% year-over-year to $8.943 billion and GAAP revenue of $9.84 billion. The analyst consensus was $9.022 billion.
Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is a &#8220;really good&#8221; company,&#8221; Cramer said. &#8220;It's just one of those companies that you just want to own it — I hate to say this — and forget about it, because that's how good it is.&#8221;
On Oct. 22, Stryker reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $2.77 per share. The company reported quarterly sales of $5.49 billion which beat the analyst consensus estimate of $5.37 billion.
Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) is &#8220;very good,&#8221; he said. &#8220;It's a great place to be, particularly with all the things that are being done with AI.&#8221;
Lantheus Holdings will host a conference call on Wednesday, Nov. 6, to discuss its financial and operating results for the third quarter.
Essential Utilities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) is a &#8220;great&#8221; company, the Mad Money host said. &#8220;That is a terrific stock.&#8221;
Essential Utilities will report earnings for the quarter ending Sept. 30, after the closing bell on Nov. 4.
Price Action:
<ul>
<li>GE Aerospace shares fell 1.6% to settle at $171.78 on Thursday.</li>
<li>Stryker shares dipped 2% to close at $356.28 on Thursday.</li>
<li>Lantheus shares gained 0.4% to settle at $109.84 during the session.</li>
<li>Essential Utilities fell 0.4% to settle at $38.60 on Thursday.</li>
<li>Cava shares fell 0.2% to close at $133.56.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

CAVA

WTRG

Jim Cramer Likes Cava Group, Calls This Utilities Stock 'Terrific'

<ul>
<li>Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival</li>
<li>Overall Response Rate was&nbsp;38.1%&nbsp;vs.&nbsp;12.0%&nbsp;for the ARPI switch arm, including&nbsp;9.3%&nbsp;Complete Responses</li>
<li>Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy&mdash;Prostate (FACT-P)</li>
<li>Interim Overall Survival Crossover Adjusted Hazard Ratio was &lt;1.00 when Assessed Using Two-Stage and Inverse Probability Censoring Weighting Methods</li>
<li>Overall Survival data continue to mature, an update is expected once data are available for&nbsp;75%&nbsp;of protocol-specified target OS events</li>
</ul>

Reported Sunday, Lantheus Unveils Phase 3 SPLASH Trial Results In PSMA-Positive Metastatic Prostate Cancer At ESMO 2024

Redburn Atlantic analyst Ed Ridley-Day initiates coverage on Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announces Price Target of $175.

Initiation

Redburn Atlantic Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $175

Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the&nbsp;Mayo Clinic&nbsp;in&nbsp;Rochester, Minnesota, will deliver an oral presentation, including additional clinical data from PNT2002's initial December 2023 readout, during the European Society of Medical Oncology (ESMO) Annual Meeting in Barcelona on Sunday, September 15, 2024. &nbsp;

Biotech

Lantheus To Present Additional Clinical Data From Phase 3 Pivotal SPLASH Trial In PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress In Barcelona On Sunday, September 15, 2024

JMP Securities analyst David Turkaly maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Market Outperform and lowers the price target from $130 to $125.

JMP Securities Maintains Market Outperform on Lantheus Holdings, Lowers Price Target to $125

Truist Securities analyst Richard Newitter maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and lowers the price target from $141 to $135.

Truist Securities Maintains Buy on Lantheus Holdings, Lowers Price Target to $135

Whales with a lot of money to spend have taken a noticeably bullish stance on Lantheus Holdings.
Looking at options history for Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $277,310 and 3, calls, for a total amount of $502,500.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $155.0 for Lantheus Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Lantheus Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Lantheus Holdings's significant trades, within a strike price range of $90.0 to $155.0, over the past month.
<h3>Lantheus Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722441659_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.5</td>
<td>$20.5</td>
<td>$20.5</td>
<td>$90.00</td>
<td>$307.5K</td>
<td>1.2K</td>
<td style="text-align: right;">350</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.4</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$90.00</td>
<td>$156.0K</td>
<td>1.2K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$20.5</td>
<td>$19.2</td>
<td>$19.2</td>
<td>$120.00</td>
<td>$67.2K</td>
<td>338</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$9.3</td>
<td>$7.4</td>
<td>$8.5</td>
<td>$110.00</td>
<td>$62.0K</td>
<td>960</td>
<td style="text-align: right;">77</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$60.5</td>
<td>$57.3</td>
<td>$57.3</td>
<td>$155.00</td>
<td>$57.3K</td>
<td>0</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Lantheus Holdings</h3>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Following our analysis of the options activities associated with Lantheus Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is Lantheus Holdings Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,250,895, with LNTH's price down by -16.19%, positioned at $92.0.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>What The Experts Say On Lantheus Holdings</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $137.75.
<ul>
<li>Maintaining their stance, an analyst from Leerink Partners continues to hold a Outperform rating for Lantheus Holdings, targeting a price of $127. </li>
<li>Consistent in their evaluation, an analyst from B. Riley Securities keeps a Buy rating on Lantheus Holdings with a target price of $146. </li>
<li>Maintaining their stance, an analyst from Jones Trading continues to hold a Buy rating for Lantheus Holdings, targeting a price of $137. </li>
<li>An analyst from Truist Securities has decided to maintain their Buy rating on Lantheus Holdings, which currently sits at a price target of $141. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lantheus Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Lantheus Holdings's Options Frenzy: What You Need to Know

Lantheus shares are trading lower after the company cut its FY24 EPS outlook.

Full Year 2024 Financial Guidance
<table align="center" cellspacing="0" style="width:100%">
<tbody>
<tr>
<td style="text-align:center; vertical-align:bottom; width:33%">&nbsp;</td>
<td style="text-align:center; vertical-align:bottom; width:33%">Guidance Issued July 31, 2024</td>
<td style="text-align:center; vertical-align:bottom; width:33%">Guidance Issued May 2, 2024</td>
</tr>
<tr>
<td style="vertical-align:bottom">FY 2024 Revenue</td>
<td style="text-align:center; vertical-align:bottom">$1.50 billion - $1.52 billion</td>
<td style="text-align:center; vertical-align:bottom">$1.50 billion - $1.52 billion</td>
</tr>
<tr>
<td style="vertical-align:bottom">FY 2024 Adjusted Fully Diluted EPS</td>
<td style="text-align:center; vertical-align:bottom">$6.60 - $6.70</td>
<td style="text-align:center; vertical-align:bottom">$7.00 - $7.20</td>
</tr>
</tbody>
</table>

Lantheus Cuts FY24 Adj. EPS Outlook Form $7.00-$7.20 To $6.60-$6.70 Vs. $7.07 Estimate, Maintains Revenue Outlook Of $1.50B-$1.52B Vs. $1.51B Estimate

David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on Lantheus (LNTH – Research Report). The associated price target is $112....

Lantheus: Strong Performance and Strategic Positioning Make It a Compelling Buy Despite Adjusted Price Target

JMP Securities lowered the firm's price target on Lantheus (LNTH) to $112 from $125 and keeps an Outperform rating on the shares. Q3 results includ...

Lantheus price target lowered to $112 from $125 at JMP Securities

Truist lowered the firm's price target on Lantheus (LNTH) to $120 from $135 and keeps a Buy rating on the shares after its Q3 results. Given that p...

Lantheus price target lowered to $120 from $135 at Truist

Lantheus Holdings: Q3 Results Were Good But Market Overreacted

Lantheus (LNTH) Holdings notes that the Centers for Medicare & Medicaid Services recently posted updated payment rates in Addendum B related to the...

Lantheus reaffirms outlook for PYLARIFY's 'blockbuster status' for 2025

In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Lantheus (LNTH – Research Report). The company's shares...

Truist Financial Issues a Buy Rating on Lantheus (LNTH)

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday. Anthony Petrone has giv...

Buy Rating Reaffirmed for Lantheus Amid Discounted Valuation and Promising Growth Catalysts

Alkermes, DaVita, Jabil, Ralph Lauren, among potential M&A candidates - BofA

Lantheus Holdings launches $250M share buyback program

Janus Henderson Global Life Sciences Fund Q3 2024 Commentary

ABBV

ACLX

ALKS

AMGN

APEI

APOG

APTV

ARGNF

ARGX

ATKR

BHVN

COLL

CWCO

FDMT

FFIV

FLYW

FOLD

HALO

HSII

INSM

JAAA

JBBB

JMBS

JSMD

JSML

LUNG

MDGL

OTTR

PCVX

PLAB

PRCT

RXST

SNYNF

SRPT

STNG

VNLA

Press Releases

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Management

Lantheus Appoints Julie Eastland as New Board Member

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Small Cap

Opinion

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Health Care

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Lantheus Reports Third Quarter 2024 Financial Results

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Comments

Lantheus Holdings

Intérêt court

Lantheus Holdings (NASDAQ:LNTH) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL